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Ngkelo A, Hoffmann RF, Durham AL, Marwick JA, Branden-
burg SM, de Bruin HG, Jonker MR, Rossios C, Tsitsiou E,
Caramori G, Contoli M, Casolari P, Monaco F, Andò F, Speciale
G, Kilty I, Chung KF, Papi A, Lindsay MA, ten Hacken NH, van
den Berge M, Timens W, Barnes PJ, van Oosterhout AJ, Adcock
IM, Kirkham PA, Heijink I. Glycogen synthase kinase-3 modula-
tion of glucocorticoid responsiveness in COPD. Am J Physiol Lung
Cell Mol Physiol 309: L1112–L1123, 2015. First published August
28, 2015; doi:10.1152/ajplung.00077.2015.—In chronic obstructive
pulmonary disease (COPD), oxidative stress regulates the inflamma-
tory response of bronchial epithelium and monocytes/macrophages
through kinase modulation and has been linked to glucocorticoid
unresponsiveness. Glycogen synthase-3 (GSK3) inactivation plays
a key role in mediating signaling processes upon reactive oxygen
species (ROS) exposure. We hypothesized that GSK3 is involved in
oxidative stress-induced glucocorticoid insensitivity in COPD. We
studied levels of phospho-GSK3-Ser9, a marker of GSK3 inacti-
vation, in lung sections and cultured monocytes and bronchial epithe-
lial cells of COPD patients, control smokers, and nonsmokers. We
observed increased levels of phospho-GSK3-Ser9 in monocytes,
alveolar macrophages, and bronchial epithelial cells from COPD
patients and control smokers compared with nonsmokers. Pharmaco-
logical inactivation of GSK3 did not affect CXCL8 or granulocyte-
macrophage colony-stimulating factor (GM-CSF) expression but re-
sulted in glucocorticoid insensitivity in vitro in both inflammatory and
structural cells. Further mechanistic studies in monocyte and bron-
chial epithelial cell lines showed that GSK3 inactivation is a com-
mon effector of oxidative stress-induced activation of the MEK/ERK-
1/2 and phosphatidylinositol 3-kinase/Akt signaling pathways leading
to glucocorticoid unresponsiveness. In primary monocytes, the mech-
anism involved modulation of histone deacetylase 2 (HDAC2) activ-
ity in response to GSK3 inactivation. In conclusion, we demonstrate
for the first time that ROS-induced glucocorticoid unresponsiveness in
COPD is mediated through GSK3, acting as a ROS-sensitive hub.
COPD; oxidative stress; inflammatory responses; monocytes; epithe-
lial cells
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) is character-
ized by chroniclung inflammation, airway remodeling, and
pulmonary emphysema, which leads to airflow limitation and
accelerated lung function decline. Current therapies fail to
prevent either disease progression or mortality. Glucocortico-
ids are widely used because of their broad anti-inflammatory
effects, but they provide relatively little therapeutic benefit in
COPD (3). The reduced responsiveness to the anti-inflamma-
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tory effects of glucocorticoids is a major barrier to effective
management of COPD patients. Therefore, there is an urgent
need to understand the underlying molecular mechanisms.
The increased oxidant burden in the lungs of COPD patients,
derived from cigarette smoke (CS) and the respiratory burst
from inflammatory cells, plays a significant role in the reduced
glucocorticoid responsiveness (4, 10, 25, 33, 41). Oxidative
stress has a profound impact on inflammation by inducing
proinflammatory mediators that attract and activate neutro-
phils, including CXCL8 and granulocyte-macrophage colony-
stimulating factor (GM-CSF). This induction is driven by
activation of redox-sensitive kinase pathways [including
MAPK and phosphatidylinositol 3-kinase (PI3K)/Akt signal-
ing] and proinflammatory transcription factors such as the
nuclear factor-B (NF-B) (8, 26, 27, 31, 32, 37). In addition,
oxidative stress can induce PI3K-dependent posttranslational
histone deacetylase 2 (HDAC2) modifications, including phos-
phorylation, resulting in proteasomal HDAC2 degradation (1,
22, 27, 33). HDAC2 can deacetylate the glucocorticoid recep-
tor (GR) as well as histones at NF-B response elements
within promoter regions of inflammatory genes (21–23). Re-
duced HDAC2 expression has been observed in the lungs and
alveolar macrophages of COPD patients and has been impli-
cated in glucocorticoid insensitivity in COPD (22, 23). In
addition to alveolar macrophages, we recently observed that
bronchial epithelial cells from COPD patients are less respon-
sive to glucocorticoids than those from healthy controls (16).
Here, proinflammatory cytokine production was effectively
suppressed by glucocorticoids in cells from healthy controls,
while this response was compromised in COPD-derived cells.
The constitutively active serine/threonine kinase glycogen
synthase-3 (GSK3) is regulated by oxidative stress and has
been linked to several inflammatory diseases (6, 20, 24).
GSK3 activity is negatively regulated by phosphorylation on
serine 9, which can be mediated by ERK1/2 MAPK and Akt
(15). As these kinase pathways are commonly involved in
oxidant-mediated responses, GSK3 may represent an impor-
tant downstream effector of oxidant-mediated signaling during
COPD inflammation. We hypothesized that GSK3 is in-
volved in oxidative stress-induced glucocorticoid responsive-
ness in COPD. We demonstrate that levels of inactive GSK3
are enhanced in monocytes, macrophages, and bronchial epi-
thelial cells from COPD patients compared with smokers and
nonsmokers and that oxidative stress-induced GSK3 inhibi-
tion regulates glucocorticoid responsiveness in both mono-
cytes/macrophages and bronchial epithelial cells.
METHODS
Human studies. Peripheral lung sections, peripheral venous blood, pri-
mary bronchial epithelial cells (PBECs), and tissue sections were isolated
from age-matched nonsmokers, smokers with normal lung function, and
COPD patients. For GSK3 phosphorylation and total staining analysis,
peripheral lung sections were collected from 21 patients with COPD, 19
smokers, and 14 nonsmokers subjects (Table 1) and from 12 COPD patients,
12 smokers, and 10 nonsmokers (Table 2), respectively. Phospho-GSK3
was also detected in tissue macrophages of severe COPD patients (Table 1).
Peripheral venous blood was collected from 10 patients with COPD, 6
smokers with normal lung function, and 7 nonsmokers (Table 3). PBECs
were obtained from 14 current and ex-smoking COPD patients with Global
Initiative for Chronic Obstructive Lung Disease (GOLD) guideline classifi-
cation stage II-IV, 16 age-matched control smokers, and 14 nonsmokers
(Table 4) (17). With the exception of the COPD stage IV patients, subjects
did not use inhaled corticosteroids, long-acting -agonists, and long-acting
anticholinergics for at least 4 wk preceding the study. The study protocol for
this part was consistent with the Research Code of the University Medical
Center Groningen (https://www.umcg.nl/SiteCollectionDocuments/English/
Researchcode/UMCG-Researchcode,%20basic%20principles%202013.pdf)
and national ethical and professional guidelines (Code of Conduct;
Dutch Federation of Biomedical Scientific Societies; https://
www.federa.org/codes-conduct).
All participants gave informed consent to a protocol approved by
the ethics committee of the Royal Brompton and Harefield National
Health Service Trust/National Heart and Lung Institute and the
University Medical Center Groningen. The Section of Respiratory
Disease at the University Hospital of Ferrara and the Pneumology
Unit at the University Hospital of Messina have ethics committee
approval for the collection and analysis of specimens from lung
resection surgery.
Cell culture. Peripheral blood mononuclear cells (PBMCs) were
isolated from whole venous blood by Histopaque (Sigma, Dorset,
UK), as previously described (27). Monocytes were isolated from
PBMCs by MACS with the Monocyte Isolation Kit II (Miltenyi
Biotec, Bergisch-Gladbach, Germany). PBECs were cultured in bron-
chial epithelium growth medium (BEGM; Lonza, Breda, The Neth-
erlands) in flasks coated with collagen and fibronectin as described
previously (19). Human bronchial epithelial (16HBE) cells were
kindly provided by Dr. G. Gruenert and grown in EMEM/10% FCS
(UCSF) (18).
Cell culture and treatments. Isolated monocytes and human mono-
cyte-macrophage cells (MonoMac6) were cultured in RPMI 1640
GlutaMAX phenol red free media (Invitrogen, Paisley, UK) with 1%
FCS, 2 mM L-glutamine, 1% nonessential amino acids, and 1%
sodium pyruvate. Primary monocytes were pretreated with U0126
(MEK/ERK-1/2 inhibitor), MK-2206 (Akt inhibitor), or IC87114
(PI3K- inhibitor) all at 1 M for 30 min and were stimulated with
hydrogen peroxide (H2O2; 100 M) for 30 min. Primary monocytes
Table 1. Characteristics of subjects for the immunohistochemical study of phospho-GS3K
Nonsmokers Smokers COPD Severe COPD
Age 67.7  8.1 70.0  6.7 69.1  6.6 70.3  2.8
Sex (M/F) 0/14 18/1 18/3 7/0
Current/former smokers N/A 9/10 7/14 3/4
Pack years N/A 49.4  32.3 40.5  20.1 50.6  11.6
FEV1, liter 2.1  0.4 2.5  0.7 2.03  0.5 1.13  0.073
FEV1, %pred 101.5  22.5 91.8  14.6 75.3  16.6 41.3  3.0
FEV1/FVC ratio, % 76.4  3.5 75.5  4.6 56.1  9.1 51.7  4.9
GOLD stage N/A N/A 8 Grade 1, 11 grade 2, 2 grade 3 All grade 3
Data are presented as means  SD. Peripheral lung tissue sections were collected from patients recruited from the Section of Respiratory Diseases of the
University Hospital of Ferrara. GS3K, glycogen synthase-3; FEV1, forced expiratory volume in 1 s; FVC: forced vital capacity. GOLD, Global Initiative for
Chronic Obstructive Lung Disease guideline classification of patients with chronic pulmonary disease (COPD); %pred, %predicted; M, male; F, female. The
FEV1/FVC ratio is after bronchodilator for subjects with COPD but not for smokers or nonsmokers.
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were pretreated with the GSK3 inhibitor CT99021 (100 nM and 1
M) for 15–120 min as indicated. To study the function of glucocor-
ticoids, primary monocytes or transfected MonoMac6 cells were
pretreated with dexamethasone (10 nM, 100 nM, and 1 M) for 30
min before being stimulated with LPS (10 ng/ml) for 16 h. Cells or
cell-free supernatants were harvested for RNA isolation, cell lysate
preparation, or measurement of cytokines.
PBECs were cultured for at least 3 wk and used at passage 3.
PBECs and 16HBE cells were passaged by trypsin, plated in 24-well
plates, and grown to 90% confluence. Subsequently, PBECs were
hormone/growth factor-deprived using basal medium (BEBM; Lonza)
supplemented with transferrin and insulin (PBECs) and 16HBE cells
were serum-deprived overnight.
PBECs and 16HBE cells were pretreated with or without 7.5%
cigarette smoke extract (CSE) for 6 h. N-acetyl-cysteine (NAC; 5
mM) was added 90 min before CSE exposure. CT99201 (10 M) was
added 30 min before CSE treatment for 6 h or budesonide (1, 10, and
100 nM) treatment for 2 h and cells were subsequently stimulated with
TNF- (10 ng/ml) for 24 h. Cells or cell-free supernatants were
harvested for RNA isolation, cell lysate preparation, or measurement
of cytokines.
Transfections. GSK3 on-target siRNA (Dharmacon) was used
according to the manufacturer’s instructions. The HA-GSK3-S9A-
pcDNA3 and HA-GSK3-K85A-pcDNA3 expression vectors were
kindly provided by Dr. J. Woodget (Toronto, Canada). The following
plasmids were obtained from Addgene: plasmid 14754-GSK3 S9A
mutant pcDNA3 (36); Addgene plasmid 14755-GSK3 K85A mutant
pcDNA3.1; or the negative control pcDNA3 construct lacking the
GSK3 insert (36).
Cigarette smoke extract. Two 3R4F research cigarettes (Tobacco
Research & Development Center, Lexington, KY) bubbled at 70 rpm
through 25 ml EMEM, using a high flow peristaltic pump (Watson
Barlow, Rotterdam, The Netherlands) represents 100% CSE. The
extract was prepared freshly for each experiment.
Quantitative RT-PCR. RNA was isolated and heme-oxygenase-1
(HO-1) mRNA expression was analyzed by real-time PCR using
Taqman (Applied Biosystems, Foster City, CA) as described previ-
ously (16). Validated probe and housekeeping genes, -2-microglobu-
lin (B2M), and peptidylprolyl isomerase A (PP1A) and TaqMan
Master Mix were purchased from Applied Biosystems.
Lung tissue processing and immunohistochemistry. Lung tissue
processing and immunohistochemistry were performed as previously
described (44). The anti-phospho-GSK3-Ser9 (sc-11757-R) and
anti-total GSK3 (sc-9166) antibodies were obtained from Santa Cruz
Biotechnology (Heidelberg, Germany). Biotinylated horse anti-rabbit
IgG secondary antibody was used (Vector BA 1000) at 1:200, and
staining was revealed using a Vectastain ABC kit (Vector PK-6100)
according to the manufacturer’s instructions.
HDAC2 activity assay. Cell lysates were prepared and subjected to
HDAC immunoprecipitation as previously described (28). Immuno-
precipitation was conducted with anti-HDAC2 antibody (Sigma).
HDAC activity in the immunoprecipitates was assessed using a
fluorometric assay kit (Biovision, Mountain View, CA). Phosphory-
lated levels of HDAC2 were measured using an anti-p-Ser394-
HDAC2 (Abcam, Cambridge, UK).
Western blot. Whole cell lysates were subjected to Western blotting
as previously described (28). p-Ser473-Akt, GSK3, phospho-
GSK3-Ser9, ERK1/2, and p-ERK1/2 antibodies were purchased
from Cell Signaling Technology (Herts, UK). Anti-human -actin
was obtained from Santa Cruz Biotechnology and anti-human
GAPDH antibody from Abcam.
GM-CSF and CXCL8 cytokine release. Levels of GM-CSF and
CXCL8 were analyzed in cell-free supernatants by sandwich ELISA
(R&D Systems, Abingdon, UK) according to the manufacturer’s
instructions.
Genome-wide mRNA expression profile. Monocytes were treated
with CT99021 (1 M), dexamethasone (10	8 M, 30 min), and LPS
(10 ng/ml) as described above and RNA (0.5 g) was extracted using
the RNeasy Mini Kit (Qiagen, Crawley, UK). The mRNA expression
profile was determined using the Agilent SurePrint G3 Human mi-
croarrays v2 following the manufacturer’s instructions.
Differential gene expression was determined using the Partek
Genomics Suite using a false discover rate 
0.05. Differences 1.2-
fold on mRNA expression were taken into consideration for our
analysis. Gene sets significantly enriched in Partek were transferred to
the Database for Annotation, Visualisation and Integrated Discovery
(DAVID) version 6.7 (http://david.abcc.ncifcrf.gov/). Pathway analy-
sis was performed by Kyoto Encyclopaedia of Genes and Genomes
(KEGG).
Statistical analysis. Data were analyzed by Friedman or Kruskal-
Wallis ANOVA and the Mann-Whitney test to determine statistical
significance of nonparametric data. For parametric data, ANOVA and
Dunnett’s posttest were used for tests between groups and the Stu-
dent’s t-test was used for tests within groups.
Table 2. Characteristics of subjects for the
immunohistochemical study of total GS3K
Nonsmokers Control smokers COPD
Age 69.1  2.5 65.4  1.9 69.5  2.1
Sex (M/F) 2/8 12/0 12/0
Current/former smokers N/A 6/6 7/5
Pack years N/A 49.1  12.1 37.9  3.3
FEV1, %pred 111.2  6.2 90.5  4.8 70.4  3.8
FEV1/FVC ratio, % 78.1  1.4 76.8  1.2 59.4  2.1
Data are presented as means  SD. Peripheral lung tissue sections were
collected from patients recruited from the Section of Respiratory Diseases of
the University Hospital of Ferrara.
Table 3. Characteristics of subjects: peripheral blood
monocytes
Nonsmokers Controls smokers COPD
Age 57  4.4 55.5  3.2 65.6  4.4
Sex M/F 3/4 4/2 8/2
Current/former smokers N/A 5/1 2/8
Pack years N/A 31  12.3 33.1  14.2
FEV1, %pred 105.6  7.5 92.2  14.5 68.65  16
FEV1/FVC ratio 72.54  3.9 73.02  8.8 58.79  15.7
Data are presented as means  SD. Peripheral venous blood was collected
from patients at the Royal Brompton hospital of London.








Age 56 (43–76) 54 (43–70) 56.5 (50–65)
Sex M/F 5/6 9/3 4/4
Pack years 0 (0–0) 39.5 (19–50) 33.5 (11–54)
Medians (range) or number. All experimental controls are included. Primary
bronchial epithelial cells (PBECs) included in the study were obtained from
Lonza or the NORM and TIP Study within the University Medical Center
Groningen. COPD patients were included on a basis of FEV1
50% of
predicted, FEV1/FVC 
70%, and 10 pack years for GOLD stage IV. All
control subjects had FEV1/FVC 70% and FEV190% of predicted. PBECs
obtained from Lonza are not indicated with FEV1/FVC and FEV1 predicted or
pack years.
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Fig. 1. Phospho (p)-glycogen synthase 3 (GSK3)-Ser9 levels are elevated in peripheral lung alveolar macrophages, peripheral blood monocytes, and primary
bronchial epithelial cells (PBECs) from chronic obstructive pulmonary disease (COPD) patients. Representative images (A) and percentage of macrophages (B)
positively stained for p-GSK3-Ser9 in peripheral lung sections from nonsmokers (n  14), smokers (n  19), mild-moderate COPD (n  21), and severe COPD
patients (n  7). Ratio of p-GSK3/total GSK3 in primary monocytes (n  6–10) with representative blots (C) and p-GSK3/GAPDH (D) and total
GSK3/GAPDH (E) with representative blots in PBECs from nonsmokers, smokers, and Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage
IV COPD patients (n  7–8). F: representative images of staining of p-GSK3 in large airway epithelial cells in peripheral lung sections from nonsmokers,
smokers, and COPD patients are shown beneath along with an isotype-stained section as a control. G: total GSK3 staining in macrophages of COPD subjects
and controls. H: percentage of GSK3-positive macrophages. P values are indicated and as tested by Kruskal-Wallis ANOVA.
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RESULTS
Increased phospho-GSK3-Ser9 levels in COPD alveolar
macrophages, monocytes, and bronchial epithelial cells. We
first assessed the levels of phosphorylated/inactive GSK3 in
peripheral lung tissue, peripheral blood monocytes and PBECs
from COPD patients, nonsmokers and smokers with normal
lung function. Phospho-GSK3-Ser9 staining was higher in
lung tissue macrophages of COPD patients (70.5  4.1%
positive) than in control smokers (46.5  6.2, P 
 0.01) and
nonsmokers (19.3  3.8, P 
 0.001) and was also higher in
control smokers than nonsmokers (Fig. 1, A and B). The levels
of phospho-GSK3 staining were even higher in macrophages
(84.9  9.8% positive, P 
 0.01) from severe COPD com-
pared with moderate COPD patients (Fig. 1B). We were unable
to obtain bronchoalveolar lavage (BAL) samples to confirm
these results in BAL macrophages using Western blotting. The
ratio of phosphorylated to total GSK3 was increased in
peripheral blood monocytes from COPD patients compared
with healthy subjects with no smoking history as determined
by Western blot analysis (0.81  0.17 vs. 3.48  0.74, P 

0.05; Fig. 1C). Furthermore, phospho-GSK3-Ser9 levels were
significantly increased in PBECs from COPD stage GOLD IV
patients (1.57  0.10, P 
 0.05) and control smokers (1.57 
0.10, P 
 0.05) compared with nonsmoking individuals
(1.05  0.05; Fig. 1D) without significant differences in total
GSK3 levels (Fig. 1E). Immunohistochemical staining also
indicated strong phospho-GSK3-Ser9 staining in bronchial
epithelium of smokers with and without COPD, although all
bronchial epithelial cells in lung tissue stained positive for
phospho-GSK3-Ser9 and we did not detect clear differences
compared with nonsmoking controls using this method (Fig.
1F). Immunostaining for total GSK3, detecting both phos-
phorylated and nonphosphorylated forms, indicated similar,
albeit less strong, increases in staining in macrophages from
smokers with and without COPD, without a significant differ-
ence between these two groups (Fig. 1, G and H). All bronchial
epithelial cells were stained, and we did not observe differ-
ences between the groups (Fig. 1G). Having shown inactiva-
tion of GSK3 in different airway cells and blood monocytes
in COPD patients, we examined the functional consequences
of this altered activation state in monocytes/macrophages and
airway epithelial cells.
GSK3 inhibition abrogates glucocorticoid responsiveness
in primary human blood monocytes. We next investigated
whether GSK3 inactivation affects the regulation of inflam-
matory cytokines. Treatment of monocytes from healthy sub-
jects with the selective GSK3 inhibitor CT99021 had no
effect on basal GM-CSF and CXCL8 release nor on the release
upon treatment with the proinflammatory stimulus LPS (Fig. 2,
A and B).
Previously, we showed that the glucocorticoid dexametha-
sone was less effective at repressing LPS-induced GM-CSF
and CXCL8 release in blood monocytes from patients with
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Fig. 2. GSK3 inhibition attenuates the anti-inflammatory action of glucocorticoids in monocytes. CT99021 does not affect baseline or LPS-induced
granulocyte-macrophage colony-stimulating factor (GM-CSF) or CXCL8 secretion in primary monocytes from non-COPD individuals. GM-CSF (A) and CXCL8
(B) levels were measured in supernatants of primary monocytes upon pretreatment with CT99021 for 30 min followed by 24 h of LPS. Treatment of monocytes
isolated from healthy subjects with CT99021 inhibits dexamethasone (Dex)-induced suppression of LPS-stimulated (C) GM-CSF and (D) CXCL8 release
(means  SE; n  6–7). P values are indicated.
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we also investigated the effect of GSK3 inactivation on
glucocorticoid responsiveness upon LPS stimulation in mono-
cytes. Of interest, dexamethasone (10 nM)-dependent inhibi-
tion of LPS-induced GM-CSF (63.9  6.7%, P 
 0.05) and
CXCL8 (24.42  6.5%, P 
 0.05) release was completely
abrogated by CT99021 (Fig. 2, C and D).
Oxidative stress induces PI3K/Akt-dependent inhibition of
GSK3 activity in monocytes. Because of our hypothesis that
oxidative stress induces glucocorticoid responsiveness, we
next examined how GSK3 activity is modulated in response
to exogenous reactive oxygen species (ROS) in primary mono-
cytes, as both H2O2 and CSE exposure reduce glucocorticoid
sensitivity in monocytes (7, 30, 31). H2O2 increased phospho-
GSK3-Ser9 levels in a time-dependent manner (Fig. 3A).
Exposure to H2O2 also activated PI3K as measured by in-
creased levels of phospho-Akt-Ser473, at earlier time points
than GSK3-Ser9 phosphorylation (Fig. 3A). Inhibition of Akt
(MK-2206) reversed the oxidant-induced inactivation of
GSK3 (Fig. 3B). Similarly, GSK3 phosphorylation was
reduced by the MEK/ERK-1/2 inhibitor U0126, indicating
involvement of the ERK1/2 pathway in the oxidant-induced
effect on GSK3 in primary monocytes (Fig. 3, A and B). We
previously showed that PI3K is responsible for the oxidant-
induced activation of Akt in monocytes (27). However, selec-
tive inhibition of PI3K with IC87114 did not affect oxidant
induction of phospho-GSK3-Ser9 in monocytes (Fig. 3B),
indicating involvement of other PI3K isoforms or signaling
mediators.
GSK3 protein knockdown and overexpression of inactive
GSK3 reduce glucocorticoid function in monocytes. To gain
further mechanistic insight in the role of GSK3 in oxidant-
induced glucocorticoid unresponsiveness in monocytes, we
used siRNA to knockdown total GSK3 levels and analyze the
anti-inflammatory actions of dexamethasone. Transfection of
MonoMac6 cells with GSK3 on-target siRNA significantly
reduced GSK3 total protein levels compared with scrambled
control siRNA (Fig. 4A). In line with the CT99021 effect,
knockdown of GSK3 significantly inhibited the ability of
dexamethasone to suppress CXCL8 expression, and the dexa-
methasone EC50 was increased from 22 to 100 nM. In addition,
the inhibitory effect of dexamethasone on LPS-stimulated
CXCL8 expression was decreased from 52.5  4.8 to 75.8 
7.1% (Fig. 4B, left). Similar effects were seen with GSK3
knockdown on the dexamethasone suppression of LPS-induced
GM-CSF secretion (Fig. 4B, right).
To validate our findings, we overexpressed the K85A kinase
dead GSK3 mutant and analyzed dexamethasone function.
MonoMac6 and primary cells produce similar levels of inflam-
matory mediators following stimulation with LPS (Fig. 4C,
left). Dexamethasone significantly reduced LPS-induced GM-
CSF release by 33.1  2.8% in MonoMac6 cells transfected
with the control pcDNA3.1. Dexamethasone had no significant
inhibitory effect on LPS-induced GM-CSF release when the
K85A GSK3 mutant was overexpressed (91.3  12.2% vs.
111.4  15.5%, Fig. 4C).
To confirm that GSK3 mediates oxidant-induced glucocor-
ticoid insensitivity in monocytes, we overexpressed a consti-
tutively active S9A GSK3 mutant in MonoMac6 cells and
analyzed dexamethasone function during H2O2 exposure. In
line with previous studies (27), the anti-inflammatory effect of
dexamethasone was significantly attenuated by H2O2 pretreat-
ment (Fig. 4D). In the presence of the active S9A mutant,
H2O2-induced dexamethasone insensitivity was suppressed,
leading to a significant (27.2  1.3%) inhibition of LPS-
stimulated GM-CSF release, similar to that observed in control
cells (26.7  2.5% inhibition; Fig. 4D).
GSK3-regulated glucocorticoid responsiveness is HDAC2-
dependent in human monocytes. Since HDAC2 has been im-
plicated in oxidative stress-induced glucocorticoid unrespon-
siveness (4), we investigated whether ROS-induced inactiva-
tion of GSK3 may lead to modulation of HDAC2 activity in
primary monocytes. Inhibition of GSK3 activity by treatment
with CT99021 reduced the activity of immunoprecipitated
HDAC2 (Fig. 5A). This reduction in HDAC2 activity corre-
lated with increased phosphorylation of serine 394 (Fig. 5B),
while HDAC2 mRNA and protein levels were not affected by
GSK3 inactivation (data not shown).
Effect of GSK3 inhibition on dexamethasone-regulated
inflammatory gene expression in human monocytes. We also
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Fig. 3. Oxidative stress induced inactivation of GSK3 is mediated via
phosphatidylinositol 3-kinase (PI3K)/Akt in primary monocytes. A: primary
monocytes from non—–COPD individuals were exposed to H2O2, which
time-dependent increase in PI3K, ERK1/2, and GSK3 phosphorylation as
detected by Western blotting. Representative blots of 4 independent experi-
ments are shown. B: GSK3 phosphorylation is PI3K/Akt and ERK1/2-
dependent in monocytes as indicated by pretreatment of the cells with the
MEK/ERK-1/2 inhibitor U0126, the Akt inhibitor MK-2206, and the PI3K
inhibitor IC87114. Densitometry was performed and p-GSK3-Ser9 levels are
expressed as ratio of total GSK3 (means  SE; n  5).
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tion of LPS-induced gene expression using gene arrays. Partek
analysis identified 17 genes that were differentially expressed
(false discovery rate 
0.05) upon CT99021 exposure.
CT99021 specifically affected genes involved in the Wnt/-
catenin signaling pathway (P  0.05) in LPS-stimulated
MonoMac6 cells (data not shown), thereby confirming the
specificity of CT99021 action. We next investigated the effect
of CT99021 on LPS/dexamethasone-treated monocytes. On-
hundred and sixty-four known genes were differentially ex-
pressed upon GSK3 inhibition in the presence of LPS/dexa-
methasone (P 
 0.05). KEGG analysis showed key pathways
that these genes regulate (Table 5). Thirteen out of the 164
genes encode for inflammatory chemokines (such as CXCL6,
CXCL3, CXCL2, and CXCL1), cytokines (such as GM-CSF
and G-CSF) and cytokine/chemokine receptors involved in the
cytokine-cytokine receptor interaction pathway (P  2.4 
10	5). Ten more genes encode for proteins involved in chemo-
kine signaling pathways (P  2  10	4), and seven genes
encode for proteins that regulate the neuro-active receptor-
ligand interaction (P  6.5  10	2).
GSK3 inhibition abrogates glucocorticoid responsiveness
in primary 16HBE cells. We previously reported that TNF--
induced GM-CSF production in PBECs from GOLD stage II
COPD patients was less responsive to the clinically used
inhaled glucocorticoid budesonide compared with nonsmoking
controls, with an intermediate effect of budesonide in PBECs
from control smokers (16). In a similar manner to monocytes,
CT99021 had no effect on GM-CSF and CXCL8 release in
PBECs from non-COPD individuals at baseline or upon stim-
ulation with TNF-, a relevant mediator of inflammation in
COPD (Fig. 6, A and B). In further line with our findings in
monocytes, pretreatment of PBECs from non-COPD individ-
uals with CT99021 resulted in complete abrogation of the
anti-inflammatory effect of budesonide on TNF--stimulated
GM-CSF and CXCL8 release (Fig. 6, C and D).
Oxidative stress leads to reduced glucocorticoid responsive-
ness, activation of the PI3K/Akt pathway, and inhibition of
GSK3 activity in bronchial epithelial cells. Because of the
limited cell numbers of primary cultures, further mechanistic
studies were performed in the human bronchial cell line
16HBE. Bronchial epithelial cells are in direct contact with
inhaled cigarette smoke, which known to induce oxidative
stress in these cells (4, 33, 41). Therefore, we studied the effect
of CSE, which is known to exert similar effects in 16HBE cells
and PBECs at least in part through oxidative stress mechanisms
(18). Exposure of 16HBE cells to CSE (7.5%) for 6 h led to a
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Fig. 4. GSK3 modulates dexamethasone function in MonoMac6 cells. A: GSK3 levels are reduced by GSK3 siRNA after 24 h of transfection. Densitometry
was performed and GSK3 levels are expressed as ratio of -actin as loading control. B: GSK3 siRNA knockdown (24 h) inhibits the concentration-dependent
suppression of LPS-induced CXCL8 (left) and GM-CSF (right) release by dexamethasone (means  SE; n  6). C: LPS-induced GM-CSF release in mock
transfected monocytes and cells transfected with the positive control pcDNA3.1 (pg/ml; means  SE; n  4), and effect of overexpression of the inactive mutant
GSK3K85A on dexamethasone suppression of LPS-induced GM-CSF release (%; means  SE; n  4). D: overexpression of the constitutively active
GSK3S9A mutant restores H2O2-induced dexamethasone unresponsiveness of GM-CSF release (means  SE; n  4).
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significant upregulation of HO-1 mRNA, a marker of oxidative
stress, which was blocked by the oxidant scavenger NAC,
confirming that CSE exposure induces oxidative stress in
epithelial cells (data not shown). In addition, CSE exposure
reduced the ability of budesonide to suppress TNF--induced
CXCL8 release (Fig. 7, A and B), which was reversed by NAC,
confirming the involvement of oxidative stress (Fig. 7C).
Similar to the effects of oxidative stress in monocytes, CSE
(7.5%) induced activation of PI3K/Akt signaling and inactiva-
tion of GSK3 in 16HBE cells, which was no longer present
upon treatment with NAC, although the difference between
CSE and CSE  NAC did not reach significance (P  0.0692).
Together, our data show that CSE-derived ROS result in
GSK3 inactivation in bronchial epithelial cells and that
GSK3 inhibition reduces glucocorticoid sensitivity of proin-
flammatory responses in both human monocytes and bronchial
epithelial cells.
Together, our data indicate that GSK3 inhibition reduces
glucocorticoid sensitivity of proinflammatory responses in
both human monocytes and bronchial epithelial cells without
modulating inflammatory mediator expression per se. The
mechanism for the effect differs between cell types.
DISCUSSION
The increased oxidant burden derived from cigarette smok-
ing in the lungs of COPD patients has been associated with
reduced glucocorticoid responsiveness. The molecular mecha-
nisms of oxidative stress-induced glucocorticoid unresponsive-
ness have remained unknown to date. Our data show, for the
first time, that levels of inactive phosphorylated GSK3 are
higher in lung macrophages, peripheral blood monocytes, and
bronchial epithelial cells from COPD patients compared with
control subjects. In both monocytes and bronchial epithelial
cells, pharmacological inactivation of GSK3 resulted in re-
duced responsiveness of inflammatory mediators to glucocor-
ticoids. We observed a difference in glucocorticoid insensitiv-
ity between nonsmoking controls and COPD patients but not
between current smokers and COPD patients or current smok-
ers and healthy controls. This indicates that smokers have an
intermediate state of sensitivity and that individuals with
COPD are more susceptible to develop steroid insensitivity
upon smoking. Furthermore, we previously observed more
pronounced glucocorticoid unresponsiveness in epithelial cells
from severe compared with moderate COPD patients (16).
Because severe COPD patients are dependent on the use of
inhaled or oral glucocorticoids, it is of importance to elucidate
the mechanisms of glucocorticoid unresponsiveness in COPD
to improve the treatment of patients with severe symptoms.
Since we observed that phospho-GSK3 levels were still
increased in PBECs from severe, ex-smoking COPD patients,
even after 2–3 wk of culture, we anticipate that there may be
persistent alterations in the regulators of GSK3 phosphoryla-
tion, resulting from rewiring of the intracellular inflammatory
pathways rather than an effect of recent exposure to the local
inflammatory milieu in the COPD lung. The antibody used to
detect GSK3 also detects GSK3; thus although we cannot
discount a role of GSK3 here, they have identical functions.
With respect to therapeutic intervention, it will be important to
further elucidate the downstream mechanisms involved in the
reduced glucocorticoid responsiveness upon GSK3 inactiva-
tion. GSK3 is involved in numerous intracellular pathways,
and preventing its inactivation, e.g., by pharmacological inhi-
bition of the PI3K/Akt or MAPK pathways, may lead to
serious side effects.
In line with our results, the activation of GSK3 has been
previously implicated in glucocorticoid-induced apoptosis in
lymphoma cells, its inactivation resulting in glucocorticoid
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Fig. 5. GSK3-regulated glucocorticoid function is histone deacetylase 2
(HDAC2)-dependent in monocytes. A: treatment of primary monocytes with
CT99021 inhibits the enzymatic activity of HDAC2 (means  SE; n  4). B:
CT99021 treatment induces p-HDAC2-Ser394 in primary monocytes. Densi-
tometry was performed and p-HDAC2 levels are expressed as ratio of total
HDAC (means  SE; n  4). IP, immunoprecipitation; WB, Western blot.
Table 5. Pathways affected by differential gene expression in response to CT99021 treatment in MonoMac6 cells
Category Term Genes (out of 164) %Total Number Benes P Value
KEGG_PATHWAY Cytokine-cytokine receptor interaction 13 7.9% 2.4E-5
KEGG_PATHWAY Chemokine signaling pathway 10 6.1% 2.0E-4
KEGG_PATHWAY Neuroactive ligand-receptor interaction 7 4.2% 6.5E-2
Kyoto Encyclopaedia of Genes and Genomes (KEGG) analysis showed 164 known genes that were differentially expressed due to GSK3 inhibition in the
presence of LPS/dexamethasone. Thirteen out of the 164 genes encode for inflammatory chemokines. Ten genes encode for proteins involved in chemokine
signaling pathways and 7 genes encode for proteins that regulate the neuroactive receptor-ligand interaction.
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not studied (35). In monocytes, GSK3 inactivation reduced
glucocorticoid suppression of proinflammatory responses by
inhibition of the enzymatic activity of HDAC2. This reduction
in activity was not associated with a change in expression but
an increase in HDAC2 phosphorylation at serine 394. Casein
kinase 2 (CK2) phosphorylates HDAC2 at serine 394 and is a
direct target of GSK3, negatively regulating its function (38).
Therefore, inactivation of GSK3 in monocyte-macrophages
may increase CK2-induced phosphorylation of HDAC2. This
may be involved in the observed glucocorticoid unresponsive-
ness towards NF-B-induced proinflammatory cytokine pro-
duction upon GSK3 inactivation in monocytes/macrophages.
Although the functions of individual HDAC2 phosphorylation
sites and the responsible kinases are unclear, the activity of this
important GR corepressor may deprive GR of a key mech-
anism by which to control inflammatory gene expression.
In line with our findings in monocytes, our data indicate that
glucocorticoid unresponsiveness is induced upon GSK3 in-
activation in airway epithelial cells and that cigarette smoke-
induced oxidative stress may be responsible for this effect. Our
combined data from monocytes and epithelial cells suggest that
GSK3 may be an important common redox sensing effector
molecule for a number of signaling pathways including MEK/
ERK-1/2 and PI3K/Akt, regulating NF-B activation, and the
subsequent inflammatory mediator release and inflammatory
cell recruitment (12, 29). These redox sensitive p38 MAPK,
ERK-1/2, and PI3K/Akt pathways can all induce GSK3
phosphorylation (8, 15) and have been implicated in glucocor-
ticoid insensitivity in COPD (5). This further corroborates the
role of GSK3 in oxidative stress-induced glucocorticoid un-
responsiveness.
The monocyte microarray data show that the anti-inflamma-
tory effects of dexamethasone are prevented in the presence of
CT99021. Not surprisingly, therefore, the effect of GSK3
inhibition on enhancing the expression of LPS-induced inflam-
matory genes was more marked in the presence of dexameth-
asone. These genes, mostly chemokines and cytokines, regu-
late signaling pathways that induce neutrophil, lymphocyte,
and macrophage activation indicating that GSK3 activity is
important for regulating multiple inflammatory pathways mod-
ulated by glucocorticoids. This supports our hypothesis that
aberrant GSK3 activity is involved in driving chronic
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Fig. 6. GSK3 inhibition attenuates the anti-inflammatory action of glucocorticoids in primary bronchial epithelial cells (PBECs). CT99021 does not affect
GM-CSF or CXCL8 secretion in PBECs. GM-CSF (A) and CXCL8 (B) levels were measured in cell-free supernatants of PBECs from non-COPD individuals
upon pretreatment with CT99021 for 30 min followed by 24 h TNF- stimulation of PBECs (means  SE; n  4–6). Pretreatment with CT99021 (30 min)
reverses budesonide (Bud)-induced suppression of TNF--stimulated GM-CSF (C) and CXCL8 (D) release in PBECs from non-COPD individuals (means 
SE; n  8).
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inflammation through enhancing glucocorticoid insensitivity in
COPD.
GSK3 inhibition also resulted in significant hits in the
neuropeptide/neurotransmitter receptor interacting pathways,
including those for the 5-hydroxytryptamine (5-HT) receptors
2b and 6 (HTR2b and HTR6), the protease-activated receptor
(PAR) family, galanin receptor 2 (Galr2), the glutamate recep-
tor delta 2 (Grid2), and GABA B receptors 1 and 2. The
neurotransmitter serotonin (5-HT) is also released from
the neuroendocrine cells of the human lung, increasingly rec-
ognized for their immunomodulatory effects outside the central
nervous system and their contribution to the pathogenesis of
autoimmune and chronic inflammatory diseases (40). The se-
rum concentration of the tryptophan, the amino acid precursor
of the 5-HT, is increased in patients with COPD (42), whereas
plasma 5-HT levels are elevated in smokers with normal lung
function but reduced in COPD patients (39). In addition,
cigarette smoke affects airway hyperresponsiveness through
5-HT in precision-cut lung slices (11). Finally, recent evidence
indicates that 5-HT suppresses efferocytosis in human alveolar
macrophages, although this appears to be independent of
HTR2B (40). COPD patients have higher maximum thrombin
levels, rates of thrombin generation, and total thrombin forma-
tion although this was not linked to severity or inflammatory
mediator expression (43). PAR-1 is activated by the thrombin,
and it is overexpressed in the alveolar macrophages from
smokers with normal lung function (34). PAR-4 is activated by
thrombin and trypsin. PAR-4 methylation and altered expres-
sion may be important in the enhanced risks associated with
cigarette smoking that continue even after cessation (45).
GABA is produced by the bronchial epithelium and contributes
to the relaxation of airway smooth muscle tone (14). GABAA
receptors are known to be expressed on bronchial epithelial
cells, mediating mucus production in response to nicotine (13),
while the loss of GABAB receptors modifies the biochemical
and behavioral responses to nicotine withdrawal (44a). How-
ever, the function of GABAB receptors in the human airways
and in COPD patients is unknown. It is increasingly evident
that there are neural-like transmitter interactions in human
bronchial epithelial cells, which may link central nervous
system-active drugs to the increased inflammation and mucin
production seen in COPD.
Taken together, our study shows that reduced GSK3 ac-
tivity in COPD monocytes-macrophages and airway epithelial
cells may contribute to cigarette smoke-induced glucocorticoid
insensitivity in the airways of COPD patients. The key nodal
function of GSK3 in integrating various ROS-induced up-
stream and downstream signaling pathways in different cell
types suggests that reversing this inactivation may constitute a
novel therapeutic strategy to improve glucocorticoid function
and thereby suppress airway inflammation in COPD.
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Fig. 7. Cigarette smoke extract (CSE)-induced oxidative stress induces budesonide unresponsiveness in TNF--stimulated 16HBE cells. A–C: pretreatment with
CSE reduces budesonide-induced suppression of TNF--stimulated CXCL8 release and pretreatment with N-acetyl-cysteine (NAC; 30 min) restores
CSE-induced budesonide unresponsiveness (means  SE; n  5). Absolute values (A), values related to the TNF--induced control (B) and percent inhibition
by budesonide (C) are shown (D) CSE induces PI3K and GSK3 phosphorylation cells, as indicated by Western blotting. Representatives of 3 independent
experiments are shown. The CSE-induced increase in GSK3 phosphorylation is abrogated by NAC pretreatment. Densitometry was performed and
p-GSK3-Ser9 levels are expressed as ratio of GAPDH as loading control (means  SE; n  6).
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